Equillium Inc. (EQ) Fundamentals

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
SHARE INFORMATION
Market Cap$ 34,414,149
Shares Outstanding34,414,149
Float17,203,157
Percent Float49.99%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -1.36
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions70
Institutional Holdings Date2022-12-31
Institutional Bought Previous 3 Months398,353
Institutional Holdings Percent57.1%
Institutional Sold Previous 3 Months525,872
Insider Holdings Date2022-12-31
Insider Bought Previous 3 Months-
Insider Holdings Percent3.6
Insider Sold Previous 3 Months-
Insider Shares Owned1,246,447
TRADING INFO
52 Week High$ 4.38
52 Week Low$ 0.79
52 Week High Change$ -75.00
21 Day Moving Average$ 1.0549
21 Day Extended Moving Average$ 1.1012
50 Day Moving Average$ 1.3126
50 Day Extended Moving Average$ 1.2892
200 Day Moving Average$ 2.0556
200 Day Extended Moving Average$ 2.1742
10 Day Average Volume91,600
20 Day Average Volume98,733
30 Day Average Volume102,653
50 Day Average Volume75,345
Alpha-0.020227
Beta1.2270
Standard Deviation0.373014
R20.034956
7 Day Price Change$ -0.11
7 Day Percent Change-9.91%
21 Day Price Change$ -0.18
21 Day Percent Change-15.25%
30 Day Price Change$ 0.11
30 Day Percent Change12.36%
Month to Date Price Change$ -0.06
Month to Date Percent Change-5.66%
Quarter to Date Price Change$ -0.06
Quarter to Date Percent Change-5.66%
180 Day Price Change$ -1.11
180 Day Percent Change-52.61%
200 Day Price Change$ -1.30
200 Day Percent Change-56.52%
Year to Date Price Change$ -0.06
Year to Date Percent Change-5.66%

Equillium Inc. (EQ) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.30
Total Debt To Equity0.40
Int Coverage-71.30
Current Ratio3.10
Leverage Ratio1.50
Quick Ratio3.00
Long Term Debt To Capital0.16
VALUATION MEASURES
PE Ratio-0.40
Enterprise Value$ 2,256,431
Price to Sales0.00
Price to Free Cash-1.00
PE High Last 5 Years0.00
Price To Book1.30
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book1.30
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-119.44
Return on Equity-164.16
Return on Capital-119.28

Equillium Inc. (EQ) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorKPMG LLP
CEOBruce D. Steel
Emplyoees45
Last AuditUQ
CIK0001746466
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address2223 Avenida De La Playa
Suite 105
La Jolla, CA 92037
Websitehttps://www.equilliumbio.com
Facsimile-
Telephone+1 858 240-1200
Emailir@equilliumbio.com


Your Recent History
NASDAQ
EQ
Equillium
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.